The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease
Open accessAbstract
Neuroinflammatory changes play a pivotal role in the progression of Parkinson's disease (PD) pathogenesis. Recent findings have suggested that activated microglia may polarize similarly to peripheral macrophages in the central nervous system (CNS), assuming a pro-inflammatory M1 phenotype or the alternative anti-inflammatory M2 phenotype via cytokine production. A skewed M1 activation over M2 has been related to disease progression in Alzheimer disease, and modulation of microglia polarization may be a therapeutic target for neuroprotection. By using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-probenecid (MPTPp) mouse model of progressive PD, we investigated dynamic changes in the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, and anti-inflammatory cytokines, such as transforming growth factor (TGF)-β and IL-10, within Iba-1-positive cells in the substantia nigra compacta (SNc). In addition, to further characterize changes in the M2 phenotype, we measured CD206 in microglia. Moreover, in order to target microglia polarization, we evaluated the effect of the peroxisome-proliferator-activated receptor (PPAR)-γ agonist rosiglitazone, which has been shown to exert neuroprotective effects on nigral dopaminergic neurons in PD models, and acts as a modulator of cytokine production and phenotype in peripheral macrophages. Chronic treatment with MPTPp induced a progressive degeneration of SNc neurons. The neurotoxin treatment was associated with a gradual increase in both TNF-α and IL-1β colocalization with Iba-1-positive cells, suggesting an increase in pro-inflammatory microglia. In contrast, TGF-β colocalization was reduced by the neurotoxin treatment, while IL-10 was mostly unchanged. Administration of rosiglitazone during the full duration of MPTPp treatment reverted both TNF-α and IL-1β colocalization with Iba-1 to control levels. Moreover, rosiglitazone induced an increase in TGF-β and IL-10 colocalization compared with the MPTPp treatment. CD206 was gradually reduced by the chronic MPTPp treatment, while rosiglitazone restored control levels, suggesting that M2 anti-inflammatory microglia were stimulated and inflammatory microglia were inhibited by the neuroprotective treatment. The results show that the dopaminergic degeneration was associated with a gradual microglia polarization to the inflammatory over the anti-inflammatory phenotype in a chronic mouse model of PD. Neuroprotective treatment with rosiglitazone modulated microglia polarization, boosting the M2 over the pro-inflammatory phenotype. PPAR-γ agonists may offer a novel approach to neuroprotection, acting as disease-modifying drugs through an immunomodulatory action in the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Varga, T., Czimmerer, Z., & Nagy, L. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.014 · Cited by 933
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
McCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 847
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese Mice
Fujisaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsuneyama, K., Nagai, Y., Takatsu, K., Urakaze, M., et al. (2009) · Diabetes · doi:10.2337/db08-1475 · Cited by 715
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms
Straus, D. S., & Glass, C. K. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.003 · Cited by 554
Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., & Nagatsu, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12706-3 · Cited by 545
Perego, C., Fumagalli, S., & De Simoni, M.-G. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-174 · Cited by 506
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Varnum, M. M., & Ikezu, T. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0181-2 · Cited by 394
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383
Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J., & Schulz, J. B. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 382
Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Rojo, A. I., Innamorato, N. G., Martín‐Moreno, A. M., De Ceballos, M. L., Yamamoto, M., & Cuadrado, A. (2010) · Glia · doi:10.1002/glia.20947 · Cited by 375
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 373
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335
Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?
Hirsch, E. C., Hunot, S., Damier, P., & Faucheux, B. (1998) · Annals of Neurology · doi:10.1002/ana.410440717 · Cited by 334
Petroske, E., Meredith, G. E., Callen, S., Totterdell, S., & Lau, Y.-S. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00295-0 · Cited by 331
Role of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331
Brodacki, B., Staszewski, J., Toczyłowska, B., Kozłowska, E., Drela, N., Chalimoniuk, M., & Stępien, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.040 · Cited by 316
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309
Watson, M. B., Richter, F., Lee, S. K., Gabby, L., Wu, J., Masliah, E., Effros, R. B., & Chesselet, M.-F. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.025 · Cited by 241
Depino, A. M., Earl, C., Kaczmarczyk, E., Ferrari, C., Besedovsky, H., Del Rey, A., Pitossi, F. J., & Oertel, W. H. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03014.x · Cited by 236
Sanchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero-Ramos, M. (2013) · ASN Neuro · doi:10.1042/an20120066 · Cited by 236
Ledeboer, A., Brev�, J. J. P., Poole, S., Tilders, F. J. H., & Van Dam, A.-M. (2000) · Glia · doi:10.1002/(sici)1098-1136(200004)30:2<134::aid-glia3>3.0.co;2-3 · Cited by 223
Sawada, M., Suzumura, A., Hosoya, H., Marunouchi, T., & Nagatsu, T. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721466.x · Cited by 223
Bernardo, A., Levi, G., & Minghetti, L. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00110.x · Cited by 222
Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2006) · The FASEB Journal · doi:10.1096/fj.05-5106com · Cited by 222
Park, S.-W., Yi, J.-H., Miranpuri, G., Satriotomo, I., Bowen, K., Resnick, D. K., & Vemuganti, R. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.113472 · Cited by 221
PPAR-γ Agonists as Regulators of Microglial Activation and Brain Inflammation
Bernardo, A., & Minghetti, L. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206780574579 · Cited by 220
Marinova‐Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06189.x · Cited by 217
KIAEI, M., KIPIANI, K., CHEN, J., CALINGASAN, N., & BEAL, M. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.10.007 · Cited by 214
Lund, S., Christensen, K. V., Hedtjärn, M., Mortensen, A. L., Hagberg, H., Falsig, J., Hasseldam, H., Schrattenholz, A., Pörzgen, P., & Leist, M. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.07.007 · Cited by 212
Role of Interleukin-4 in Regulation of Age-related Inflammatory Changes in the Hippocampus
Nolan, Y., Maher, F. O., Martin, D. S., Clarke, R. M., Brady, M. T., Bolton, A. E., Mills, K. H. G., & Lynch, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412170200 · Cited by 209
Barcia, C., Bahillo, A. S., Fernández‐Villalba, E., Bautista, V., Poza Y Poza, M., Fernández‐Barreiro, A., Hirsch, E. C., & Herrero, M. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206
Luo, Y., Yin, W., Signore, A. P., Zhang, F., Hong, Z., Wang, S., Graham, S. H., & Chen, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03758.x · Cited by 203
Barcia, C., Ros, C. M., Annese, V, Gómez, A., Ros-Bernal, F., Aguado-Llera, D., Martínez-Pagán, M. E., de Pablos, V, Fernandez-Villalba, E., & Herrero, M. T. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.17 · Cited by 203
PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease
Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., & Carta, A. R. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06657.x · Cited by 200
Self-citationLuna-Medina, R., Cortes-Canteli, M., Alonso, M., Santos, A., Martínez, A., & Perez-Castillo, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414390200 · Cited by 190
Swanson, C. R., Joers, V., Bondarenko, V., Brunner, K., Simmons, H. A., Ziegler, T. E., Kemnitz, J. W., Johnson, J. A., & Emborg, M. E. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-91 · Cited by 186
Glia, cytokines, and neurotoxicity.
Chao, C. C., Hu, S., & Peterson, P. K. (1995) · PubMed · Cited by 175
Leal, M. C., Casabona, J. C., Puntel, M., & Pitossi, F. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00053 · Cited by 172
Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology
Hoozemans, J. J. M., Veerhuis, R., Rozemuller, J. M., & Eikelenboom, P. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.001 · Cited by 168
Luchtman, D. W., Shao, D., & Song, C. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.04.021 · Cited by 167
Mogi, M., Harada, M., Kondo, T., Narabayashi, H., Riederer, P., & Nagatsu, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11686-q · Cited by 165
Ezcurra, A. L. D. L., Chertoff, M., Ferrari, C. C., Graciarena, M., & Pitossi, F. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.018 · Cited by 164
Arimoto, T., Choi, D., Lü, X., Liu, M., Nguyen, X. V., Zheng, N., Stewart, C. A., Kim, H., & Bing, G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.04.011 · Cited by 163
Walsh, S. R., Finn, D. P., & Dowd, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.005 · Cited by 160
Regulation of microglial activation by TGF-β, IL-10, and CSF-1
Lodge, P. A., & Sriram, S. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.60.4.502 · Cited by 156
Carta, A. R., Frau, L., Pisanu, A., Wardas, J., Spiga, S., & Carboni, E. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.046 · Cited by 148
Self-citationPratt, B. M., & McPherson, J. M. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00018-x · Cited by 148
Bee Venom and Its Component Apamin as Neuroprotective Agents in a Parkinson Disease Mouse Model
Alvarez‐Fischer, D., Noelker, C., Vulinović, F., Grünewald, A., Chevarin, C., Klein, C., Oertel, W. H., Hirsch, É. C., Michel, P. P., & Hartmann, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061700 · Cited by 138
Xing, B., Xin, T., Hunter, R. L., & Bing, G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-4 · Cited by 127
Diab, A., Hussain, R. Z., Lovett‐Racke, A. E., Chavis, J. A., Drew, P. D., & Racke, M. K. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.010 · Cited by 125
Lofrumento, D. D., Saponaro, C., Cianciulli, A., Nuccio, F. D., Mitolo, V., Nicolardi, G., & Panaro, M. A. (2010) · NeuroImmunoModulation · doi:10.1159/000320027 · Cited by 118
Circulating interleukin-10 and interleukin-12 in Parkinson’s disease
Rentzos, M., Nikolaou, C., Andreadou, E., Paraskevas, G. P., Rombos, A., Zoga, M., Tsoutsou, A., Boufidou, F., Kapaki, E., & Vassilopoulos, D. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01103.x · Cited by 114
Luchtman, D. W., Meng, Q., & Song, C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.09.033 · Cited by 111
Unbalanced M1/M2 Phenotype of Peripheral Blood Monocytes in Obese Diabetic Patients
Satoh, N., Shimatsu, A., Himeno, A., Sasaki, Y., Yamakage, H., Yamada, K., Suganami, T., & Ogawa, Y. (2009) · Diabetes Care · doi:10.2337/dc09-1315 · Cited by 103
GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action
Schober, A., Peterziel, H., von Bartheld, C. S., Simon, H. H., KRIEGLSTEIN, K. G., & Unsicker, K. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.005 · Cited by 98
KRIEGLSTEIN, K. G., Suter‐Crazzolara, C., Hötten, G., Pohl, J., & Unsicker, K. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490420516 · Cited by 97
Xu, J., & Drew, P. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1904 · Cited by 91
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease
Schintu, N., Frau, L., Ibba, M., Garau, A., Carboni, E., & Carta, A. R. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9061-x · Cited by 89
Self-citationKim, S. R., Lee, K. S., Park, H. S., Park, S. J., Min, K. H., Jin, S. M., & Lee, Y. C. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.017160 · Cited by 87
Human Interleukin-10 Gene Transfer Is Protective in a Rat Model of Parkinson's Disease
Johnston, L. C., Su, X., Maguire‐Zeiss, K. A., Horovitz, K., Ankoudinova, I., Guschin, D. Y., Hadaczek, P., Federoff, H. J., Bankiewicz, K. S., & Forsayeth, J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.113 · Cited by 81
Modulating Microglia Activity with PPAR-γ Agonists: A Promising Therapy for Parkinson’s Disease?
Carta, A. R., & Pisanu, A. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9342-7 · Cited by 79
Self-citationCarta, A. R., Tronci, E., Pinna, A., & Morelli, M. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03944.x · Cited by 70
Self-citationPPAR-γ: Therapeutic Prospects in Parkinson's Disease
Carta, A. R. (2013) · Current Drug Targets · doi:10.2174/1389450111314070004 · Cited by 70
Self-citationCiesielska, A., Joniec‐Maciejak, I., Przybyłkowski, A. M., Gromadzka, G., Iwona, Członkowska, A., & Członkowski, A. (2003) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2003-1461 · Cited by 68
Regulation of microglia effector functions by tumor necrosis factor signaling
Harms, A. S., Lee, J., Nguyen, T. A., Chang, J., Ruhn, K. M., Treviño, I., & Tansey, M. G. (2011) · Glia · doi:10.1002/glia.21254 · Cited by 55
TGF-β in Dopamine Neuron Development, Maintenance and Neuroprotection
Roussa, E., Halbach, O. V. B. U., & KRIEGLSTEIN, K. G. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0322-8_8 · Cited by 50
Patzer, A., Zhao, Y., Stöck, I., Gohlke, P., Herdegen, T., & Čulman, J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06478.x · Cited by 50
Andrews, Z. B., Zhao, H., Frugier, T., Meguro, R., Grattan, D. R., Koishi, K., & McLennan, I. S. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.09.001 · Cited by 35
Anti‐Inflammatory and Antidiabetic Roles of PPARγ
Pascual, G., Sullivan, A. L., Ogawa, S., Gamliel, A., Perissi, V., Rosenfeld, M. G., & Glass, C. K. (2007) · Novartis Foundation symposium · doi:10.1002/9780470985571.ch16 · Cited by 33
González-Aparicio, R., Flores, J. A., & Fernández‐Espejo, E. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.08.016 · Cited by 33
Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson’s disease
Goris, A., Williams‐Gray, C. H., Foltynie, T., Brown, J., Maranian, M. J., Walton, A., Compston, D. A. S., Barker, R., & Sawcer, S. J. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0414-6 · Cited by 27
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Role of ROS and RNS Sources in Physiological and Pathological Conditions
Di Meo, S., Reed, T. T., Venditti, P., & Victor, V. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1245049 · Cited by 1,614
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
“PPAR-γ modulates the production of both pro- and anti-inflammatory cytokines in microglia, and up-regulate the M2 marker Arg-1, acting as a crucial regulator in M2 polarization (Ahmadian et al., 2013; Pisanu et al., 2014; Xu et al., 2015; Song et al., 2016; Song and Suk, 2017).”
BackgroundNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Oxidative stress and Parkinson’s disease
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878
Metadata
- Authors
- Pisanu, A., Lecca, D., Mulas, G., Wardas, J., Simbula, G., Spiga, S., & Carta, A. R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 71
- Pages
- 280-291
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2065336907
- Cited by
- 268
- References
- 83
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.